{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:28:23Z","timestamp":1793330903060,"version":"4.5.0"},"reference-count":20,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["Indian J Dermatol Venereol Leprol"],"DOI":"10.25259\/ijdvl_867_2024","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T05:33:00Z","timestamp":1733981580000},"page":"226-230","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bimekizumab: A novel FDA approved dual IL-17 A\/F inhibitor for moderate to severe psoriasis"],"prefix":"10.25259","volume":"91","author":[{"given":"Febin","family":"Ashraf","sequence":"first","affiliation":[{"name":"Department of Dermatology, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simin Muhammed","family":"Kutty","sequence":"additional","affiliation":[{"name":"Department of Paediatric Dermatology, Aspire Children\u2019s Speciality Centre, Calicut, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2024,12,11]]},"reference":[{"key":"10.25259\/IJDVL_867_2024\/ref-1","doi-asserted-by":"publisher","first-page":"595","DOI":"10.4103\/0378-6323.72443","article-title":"Psoriasis in India: Prevalence and pattern","volume":"76","author":"Dogra","year":"2010","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.25259\/IJDVL_867_2024\/ref-2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2147\/PTT.S367744","article-title":"Bimekizumab for the treatment of psoriasis: A review of the current knowledge","volume":"12","author":"Ruggiero","year":"2022","journal-title":"Psoriasis (Auckl)"},{"key":"10.25259\/IJDVL_867_2024\/ref-3","doi-asserted-by":"publisher","first-page":"694","DOI":"10.36849\/JDD.8381","article-title":"Rapid remission of plaque psoriasis with bimekizumab treatment","volume":"23","author":"Abdin","year":"2024","journal-title":"J Drugs Dermatol"},{"key":"10.25259\/IJDVL_867_2024\/ref-4","doi-asserted-by":"publisher","first-page":"e003855","DOI":"10.1136\/rmdopen-2023-003855","article-title":"Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL","volume":"10","author":"Coates","year":"2024","journal-title":"RMD Open"},{"key":"10.25259\/IJDVL_867_2024\/ref-5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/ard-2023-224803","article-title":"Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies","volume":"83","author":"Baraliakos","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_867_2024\/ref-6","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","article-title":"Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): Two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials","volume":"403","author":"Kimball","year":"2024","journal-title":"Lancet"},{"key":"10.25259\/IJDVL_867_2024\/ref-7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jdcr.2023.05.043","article-title":"A case of scalp psoriasis resistant to ixekizumab treated with bimekizumab","volume":"38","author":"Megna","year":"2023","journal-title":"JAAD Case Rep"},{"key":"10.25259\/IJDVL_867_2024\/ref-8","doi-asserted-by":"publisher","first-page":"e2024052","DOI":"10.5826\/dpc.1402a52","article-title":"Bimekizumab for the treatment of plaque psoriasis with involvement of genitalia: A 16-week multicenter real-world experience \u2013 IL PSO (Italian Landscape Psoriasis)","volume":"14","author":"Orsini","year":"2024","journal-title":"Dermatol Pract Concept"},{"key":"10.25259\/IJDVL_867_2024\/ref-9","doi-asserted-by":"publisher","first-page":"e15952","DOI":"10.1111\/dth.15952","article-title":"Sub-erythrodermic psoriasis successfully treated with bimekizumab: A case report","volume":"35","author":"Valenti","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.25259\/IJDVL_867_2024\/ref-10","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1111\/1346-8138.16866","article-title":"Two cases of generalized pustular psoriasis successfully treated with bimekizumab","volume":"50","author":"Hagino","year":"2023","journal-title":"J Dermatol"},{"key":"10.25259\/IJDVL_867_2024\/ref-11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/jamadermatol.2023.5051","article-title":"Treatment of severe palmoplantar pustular psoriasis with bimekizumab","volume":"160","author":"Passeron","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.25259\/IJDVL_867_2024\/ref-12","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/ddg.15252","article-title":"Bimekizumab in refractory pityriasis rubra pilaris","volume":"22","author":"Kromer","year":"2024","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.25259\/IJDVL_867_2024\/ref-13","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.3390\/jcm13082250","article-title":"Successful treatment with bimekizumab of a psoriatic patient undergoing hemodialysis: A case report and review of the literature","volume":"13","author":"Bernardini","year":"2024","journal-title":"J Clin Med"},{"key":"10.25259\/IJDVL_867_2024\/ref-14","author":"U.S. Food and Drug Administration","year":"2024","journal-title":"Bimekizumab injection prescribing information"},{"key":"10.25259\/IJDVL_867_2024\/ref-15","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): Efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo-controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"10.25259\/IJDVL_867_2024\/ref-16","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): A multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"10.25259\/IJDVL_867_2024\/ref-17","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1056\/NEJMc2113092","article-title":"Bimekizumab versus Adalimumab in Plaque Psoriasis","volume":"385","author":"Griffith","year":"2021","journal-title":"N Engl J Med"},{"key":"10.25259\/IJDVL_867_2024\/ref-18","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"key":"10.25259\/IJDVL_867_2024\/ref-19","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1093\/bjd\/ljad035","article-title":"Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial","volume":"188","author":"Strober","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_867_2024\/ref-20","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/bjd\/ljad429","article-title":"Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: Pooled data from up to 3 years of treatment in randomized phase III trials","volume":"190","author":"Gordon","year":"2024","journal-title":"Br J Dermatol"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/bimekizumab-a-novel-fda-approved-dual-il-17-a-f-inhibitor-for-moderate-to-severe-psoriasis\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/bimekizumab-a-novel-fda-approved-dual-il-17-a-f-inhibitor-for-moderate-to-severe-psoriasis\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T11:18:05Z","timestamp":1739963885000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/bimekizumab-a-novel-fda-approved-dual-il-17-a-f-inhibitor-for-moderate-to-severe-psoriasis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,11]]},"references-count":20,"alternative-id":["10.25259\/IJDVL_867_2024"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_867_2024","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,11]]},"article-number":"226"}}